ArticleCell death & disease2026
Functional analysis of the human miRNome in non-small cell lung cancer unveils a novel miR-92b-3p/NOTCH3 axis that drives tumor progression.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide. MicroRNAs, endogenous non-coding RNA of ~22 nucleotides, play key regulatory roles in lung cancer-related mechanisms and represent promising diagnostic and prognostic biomarkers, as well as potential therapeutic agents. However, a comprehensive functional screening of human miRNAs in lung cancer was missing. To tackle this, we performed a lentiviral-based miRNA screening (~2500 microRNAs) of lung adenocarcinoma (LUAD) i.e. the most frequent lung cancer subtype. We discovered and annotated miRNAs functionally associated with proliferation, migration, and invasion of LUAD cells. We then integrated our functional miRNA screening with transcriptomic and clinical data from a large LUAD patient cohort (TCGA-LUAD), along with spatial transcriptomics (ST) of in-house LUAD samples. This approach enabled us to identify phenotype-specific miRNA signatures and develop a 15-miRNA risk score predictive of poor overall survival (HR = 2.48, p < 0.0001). Among these, miR-92b-3p, a less studied member of the oncogenic miR-17~92 cluster, emerged as a critical driver of LUAD progression. Transcriptomics analysis revealed that miR-92b-3p overexpression increase NOTCH3 signaling activation. The inhibition of NOTCH3 signaling, either genetically or pharmacologically, abrogated the pro-migratory and invasive effects of miR-92b-3p. In summary, our study provides a systematic functional annotation of the human miRNome in LUAD and identifies a novel miR-92b-3p/NOTCH3 axis that contributes to LUAD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.